Kythera Biopharmaceuticals Presents Positive Data From Two Phase 2 Studies With ATX-101

LOS ANGELES--(BUSINESS WIRE)--KYTHERA Biopharmaceuticals, Inc. (KYTHERA) today presented detailed results from two double-blind Phase 2 studies, each designed to evaluate the safety and effectiveness of ATX-101, a first-in-class injectable drug for the reduction of small volumes of fat. Top-line results from these studies, which examined use of ATX-101 for reduction of unwanted localized fat deposits under the chin (submental fat), were announced in January 2009 (http://www.kytherabiopharma.com/press_releases.html).